

SUPPLEMENTAL REFERENCES

- S1. Mahajan R, Lipton M, Broglie L, et al. Eculizumab treatment for renal failure in pediatric patient with COVID-19. *J. Nephrol.* 2020; 26: 1-4
- S2. Le Clech A, Simon-Tillaux N, Provôt F, et al. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. *Kidney Int:* 2019; 95:1443-1452
- S3. Yu J, Yuan X, Chen H, et al. Direct activation of the alternative complement pathway by SRAS-CoV-2 spike proteins is blocked by factor D inhibition. *Blood* 2020; 136 (18):2080-89
- S4. Roumenina L, Frimat M, Miller E, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. *Blood* 2012; 119 (18):4182-4191
- S5. Bresin E, Rurali E, Caprioloi J, et al. Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype. *JASN* 2013 ; 24(3) 475-486
- S6. Ellithi M, Shahid M, Abdullah HM, et al. Complement C3 mutation causing atypical hemolytic uremic syndrome successfully treated with eculizumab. *Hematol Transfus Cell Ther.* 2020; 25: S2531-1379(20) 30028-6